Home

Invest

Tools

Raise

Discover

Partner

Blog

Planify Feed

Important update for Pharmeasy investors

18 November 2021

After a horrendous start of Paytm, we are again cautioning investors on Pharmeasy.

Pharmeasy Consolidated Results (including all subsidiaries) as per March,2021
Total Revenue => ₹4,363.2 cr
Total Consolidated Loss (including all subsidiaries) => ₹1,548.5 cr
Total Debt on 30th June,2021 => ₹2,772.61 cr

This means on every 1 cr sale of medicine, lab tests (including all subsidiaries), company incur a loss of 35.49 Lacs.

People should be cautious while investing in Pharmeasy stocks at such steep valuations or exit before the stock crashes.

Stay Connected, Stay Informed –

Join Our

Channel!

Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.

Pre Ipo

Upcoming IPO

Unicorn

Planify Capital Limited

MiQB, Plot 23, Sector 18, Maruti Industrial Development Area, Opposite VLCC corporate office, Gurugram, Haryana 122015

Registration No.

Mutual Fund License No.:

ARN-164419

IRDA Code (1):

ABLIC1003123454

IRDA Code (2):

ABLIC1003131639

Startup India Certificate No.:

DIPP93786

Name of the Fund:

VENTUREX FUND l

SEBI Registration No.:

IN/AIF1/24-25/1565

Name of Fund Manager:

Rajesh Singla

Maneesh Nath

Ishima Singla

Company

Team

About Us

Investor Risk

Channel Partner

Careers

Sitemap

Media

Offers

Planify Enterprises Private Limited
Planify Capital Limited

Licensed By

Cancellation & Refund |

Terms & Conditions |

Disclaimer

in India